MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Frequently asked questions
What sector does MediciNova Inc (4875) operate in?
MediciNova Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is MediciNova Inc (4875) current stock price?
As of the latest data, MediciNova Inc stock price is ¥239, with a previous close of ¥237. MediciNova Inc gained ¥2 in the last trading session, representing a 0.84% increase.
What is MediciNova Inc (4875) current market capitalization?
MediciNova Inc market cap is approximately 11.76 billion.
What is MediciNova Inc (4875) Earnings Per Share (EPS)?
The trailing EPS is -¥33, and the forward EPS is -¥72.
What is MediciNova Inc (4875) EBITDA?
MediciNova Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -2.51 million.
Does MediciNova Inc (4875) pay dividends?
No. MediciNova Inc does not pay a dividend.
How did MediciNova Inc (4875) perform in its most recent earnings report?
In the last report (June 30, 2026), MediciNova Inc posted an EPS surprise of 23.59% and a revenue surprise of 514.36%.
When is MediciNova Inc (4875) next earnings report?
MediciNova Inc is expected to release its next earnings report on September 30, 2026.
What is MediciNova Inc (4875) beta (volatility) score?
MediciNova Inc has a beta of 0.620, indicating lower volatility than the overall market.
